Destiny Pharma PLc

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

G27357105

SEDOL

BDHSP57

CIK

N/A

www.destinypharma.com

LEI:

FIGI: BBG00HMKFQ27

DEST

Destiny Pharma PLc

GICS: - · Sector: Health Care · Sub-Sector: Health Care

NAME

Destiny Pharma PLc

ISIN

GB00BDHSP575

TICKER

DEST

MIC

AIMX

REUTERS

DEST.L

BLOOMBERG

DEST LN

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.

Tue, 20.08.2024

20th Aug 2024 JPJ: DEST ISIN: GB00BDHSP575 Destiny Pharma plc ("Destiny Pharma" or "the Company") Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascular Surgery Patients. Brighton,...

Research & Analysis

Wed, 14.08.2024

13th Aug 2024 JPJ: DEST ISIN: GB00BDHSP575 Destiny Pharma plc("Destiny Pharma" or "the Company") Destiny Pharma initiates research to explore XF drug potential for CF Study to investigate the potential of XF-73 to treat MRSA infection in people with cystic fibrosis Brighton, United Kingdom – 14 August 2024 – Destiny Pharma (JP...

Research & Analysis

Tue, 13.08.2024

13th Aug 2024 JPJ: DEST ISIN: GB00BDHSP575 Destiny Pharma plc ("Destiny Pharma" or "the Company") Shares now trading on JP Jenkins London, UK, 13th Aug 2024 - Destiny Pharma plc (JPJ: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life-threatening in...

Research & Analysis

Mon, 21.11.2022

Contact DetailsProactiveProactive UK Ltd+44 20 7989 0813uk@proactiveinvestors.comNews Source: News Direct 21.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.

Research & Analysis

Mon, 21.11.2022

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Destiny Pharma PLc

Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula

Destiny Pharma initiates research to explore XF drug potential for CF

Destiny Pharma plc shares now trading on JP Jenkins

Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections

Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections

Newsletter